Jean‐Pierre Delord
About
Jean‐Pierre Delord is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Jean‐Pierre Delord has authored 260 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Oncology, 87 papers in Pulmonary and Respiratory Medicine and 66 papers in Molecular Biology. Recurrent topics in Jean‐Pierre Delord's work include Cancer Immunotherapy and Biomarkers (54 papers), Colorectal Cancer Treatments and Studies (48 papers) and Lung Cancer Treatments and Mutations (47 papers). Jean‐Pierre Delord is often cited by papers focused on Cancer Immunotherapy and Biomarkers (54 papers), Colorectal Cancer Treatments and Studies (48 papers) and Lung Cancer Treatments and Mutations (47 papers). Jean‐Pierre Delord collaborates with scholars based in France, United States and Switzerland. Jean‐Pierre Delord's co-authors include Sarina A. Piha‐Paul, Bettina Couderc, Benoît Thibault, Magali Castells, Ronnie Shapira‐Frommer, Hyun Cheol Chung, Antoîne Italiano, Scott K. Pruitt, Carlos Gomez‐Roca and Willeke Ros and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Jean‐Pierre Delord
253 papers receiving 8.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jean‐Pierre Delord France | 43 | 5.5k | 2.2k | 2.0k | 1.7k | 1.1k | 260 | 8.4k | ||
| Christophe Le Tourneau France | 46 | 4.9k 0.9× | 2.1k 1.0× | 2.3k 1.1× | 1.3k 0.7× | 1.6k 1.5× | 335 | 8.7k | ||
| Emiliano Calvo Spain | 45 | 6.0k 1.1× | 3.1k 1.4× | 2.7k 1.4× | 1.7k 1.0× | 1.1k 1.0× | 340 | 9.3k | ||
| Amreen Husain United States | 32 | 4.7k 0.8× | 1.5k 0.7× | 1.7k 0.8× | 1.4k 0.8× | 1.4k 1.3× | 74 | 8.2k | ||
| Michael J. Pishvaian United States | 40 | 3.8k 0.7× | 1.9k 0.9× | 1.1k 0.6× | 831 0.5× | 1.5k 1.3× | 216 | 5.8k | ||
| Amanda Psyrri Greece | 48 | 3.7k 0.7× | 2.5k 1.1× | 1.7k 0.8× | 732 0.4× | 1.5k 1.4× | 251 | 7.2k | ||
| Ronnie Shapira‐Frommer Israel | 35 | 7.0k 1.3× | 2.6k 1.2× | 1.0k 0.5× | 1.8k 1.1× | 1.1k 1.0× | 137 | 8.8k | ||
| P Stieber Germany | 49 | 3.2k 0.6× | 2.6k 1.2× | 1.4k 0.7× | 984 0.6× | 1.8k 1.6× | 214 | 7.1k | ||
| Dimitrios Pectasides Greece | 43 | 2.9k 0.5× | 1.7k 0.8× | 1.2k 0.6× | 690 0.4× | 700 0.6× | 227 | 6.1k | ||
| Shumei Kato United States | 38 | 4.5k 0.8× | 2.2k 1.0× | 2.4k 1.2× | 1.3k 0.8× | 2.6k 2.3× | 174 | 7.5k | ||
| Michael Millward Australia | 48 | 4.4k 0.8× | 3.2k 1.5× | 1.9k 1.0× | 1.2k 0.7× | 1.3k 1.2× | 277 | 7.7k |
Countries citing papers authored by Jean‐Pierre Delord
Since
Specialization
Citations
This map shows the geographic impact of Jean‐Pierre Delord's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Pierre Delord with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Pierre Delord more than expected).
Fields of papers citing papers by Jean‐Pierre Delord
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jean‐Pierre Delord. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Pierre Delord. The network helps show where Jean‐Pierre Delord may publish in the future.
Co-authorship network of co-authors of Jean‐Pierre Delord
This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Pierre Delord. A scholar is included among the top collaborators of Jean‐Pierre Delord based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Pierre Delord. Jean‐Pierre Delord is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Razak, Albiruni Ryan Abdul, Hung‐Ming Wang, Jang‐Yang Chang, et al.. (2023). A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Targeted Oncology. 18(6). 853–868.
2.
Garralda, Elena, Do Youn Oh, Antoîne Italiano, et al.. (2023). Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103). The Journal of Clinical Pharmacology. 64(5). 544–554.
3.
Tourneau, Christophe Le, Frédéric Rolland, Olivier Capitain, et al.. (2023). Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.. Journal of Clinical Oncology. 41(16_suppl). 2630–2630.
4.
Champiat, Stéphane, Philippe A. Cassier, Nuria Kotecki, et al.. (2023). Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors. Cancer Research. 83(7_Supplement). 2129–2129.
5.
Subbiah, Vivek, Irene Braña, Alessandra Longhi, et al.. (2022). Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clinical Cancer Research. 28(13). 2762–2770.
6.
Petrylak, Daniel P., Yohann Loriot, David R. Shaffer, et al.. (2021). Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research. 27(12). 3360–3369.
7.
Strosberg, Jonathan, Nobumasa Mizuno, Toshihiko Doi, et al.. (2020). Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clinical Cancer Research. 26(9). 2124–2130.
8.
Montfort, Anne, Thomas Filleron, Cécile Pagès, et al.. (2020). Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clinical Cancer Research. 27(4). 1037–1047.
9.
Tourneau, Christophe Le, Yungan Tao, Carlos Gomez‐Roca, et al.. (2020). Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 26(24). 6429–6436.
10.
Chung, Hyun Cheol, Willeke Ros, Jean‐Pierre Delord, et al.. (2019). Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology. 37(17). 1470–1478.
11.
Bahleda, Rastislav, Andréa Varga, Yann Bergé, et al.. (2018). Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. British Journal of Cancer. 118(3). 344–352.
12.
Martin, Nicolas, Nicolás Isambert, Carlos Gomez‐Roca, et al.. (2018). Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. Cancer Chemotherapy and Pharmacology. 82(6). 979–986.
13.
Schmid, Peter, Cristina Cruz, Fadi S. Braiteh, et al.. (2017). Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Research. 77(13_Supplement). 2986–2986.
14.
Stathis, Anastasios, Emanuele Zucca, Mohamed Békradda, et al.. (2016). Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discovery. 6(5). 492–500.
15.
Birzele, Fabian, Edgar Voß, Adam Nopora, et al.. (2015). CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clinical Cancer Research. 21(12). 2753–2762.
16.
Thomas, Fabienne, Paul Delmar, S. Vergèz, et al.. (2012). Gene expression profiling on pre‐ and post‐erlotinib tumors from patients with head and neck squamous cell carcinoma. Head & Neck. 35(6). 809–818.
17.
Bennouna, Jaafar, Christophe Borg, Jean‐Pierre Delord, et al.. (2011). Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study. Clinical Colorectal Cancer. 11(1). 38–44.
18.
Vergèz, S., Jean‐Pierre Delord, Fabienne Thomas, et al.. (2010). Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro- D -glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer. Clinical Cancer Research. 16(17). 4434–4445.
19.
Delord, Jean‐Pierre, et al.. (2007). Absolute bioavailability of an oral form of vinflunine, a first phase I trial. Molecular Cancer Therapeutics. 6.
20.
Léger, F., Sophie Séronie-Vivien, Isabelle Lochon, et al.. (2002). Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing. European Journal of Cancer. 38(1). 52–56.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Christophe Le Tourneau Breakdown of academic impact, for papers by Emiliano Calvo Breakdown of academic impact, for papers by Amreen Husain Breakdown of academic impact, for papers by Michael J. Pishvaian Breakdown of academic impact, for papers by Amanda Psyrri Breakdown of academic impact, for papers by Ronnie Shapira‐Frommer Breakdown of academic impact, for papers by P Stieber Breakdown of academic impact, for papers by Dimitrios Pectasides Breakdown of academic impact, for papers by Shumei Kato Breakdown of academic impact, for papers by Michael Millward